Online inquiry

IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6911MR)

This product GTTS-WQ6911MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets Alkaline phosphatase substitute gene. The antibody can be applied in Hypophosphatasia (HPP) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000478.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 249
UniProt ID P05186
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6911MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4931MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ12699MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ3335MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ12606MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ15583MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ4598MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ7628MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ2049MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AHLX-20
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW